Recent developments in second and third line therapy of metastatic renal cell carcinoma
- 31 March 2016
- journal article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 16 (5) , 469-471
Abstract
Renal cell carcinoma (RCC) represents 2–3% of all adult malignancies. Over the last few years, many agents such as VEGF- and mTOR-inhibitor have been developed for the treatment of metastatic RCC. ...Keywords
This publication has 13 references indexed in Scilit:
- CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).Journal of Clinical Oncology, 2016
- Cabozantinib versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving NivolumabJournal of Clinical Oncology, 2015
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapyExpert Opinion on Biological Therapy, 2013
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Molecular mechanisms of T‐cell toleranceImmunological Reviews, 2011
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 2007